Prescribing rates for stimulants that treat attention-deficit/hyperactivity disorder (ADHD) have increased significantly over the past decade, with some of the largest increases reported during the COVID-19 pandemic. A… read more.
Research led by the University of Southampton has found that medications play an important role in improving the quality of life of people with ADHD, but the authors… read more.
Epidemiologists in Spain have found a new link between childhood sleep patterns and behaviour, with implications for the understanding of attention deficit hyperactivity disorder (ADHD) in preadolescence. The… read more.
Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, announced the FDA has approved Onyda XR (clonidine hydrochloride),… read more.
Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and without attention-deficit/hyperactivity disorder (ADHD), researchers found significant differences in nine brain white matter tracts… read more.
Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use. A recent clinical… read more.
Attention-deficit/hyperactivity disorder (ADHD) is among the most common pediatric neurodevelopmental disorders. In 2019, nearly 10% of United States (U.S.) children had a diagnosis of ADHD. Approximately 3.3 million… read more.
New research from the University of Cambridge and the University of Melbourne, published in Science Advances, shows neurotypical workers and students taking cognitive enhancers, or ‘smart’ drugs, may actually be… read more.
U.S. middle and high schools with the most students taking prescription stimulants to treat ADHD also had, overall, the highest percentage of students who misused prescription stimulants within… read more.
There is new evidence that a 50-year-old blood pressure drug could find new purpose as a treatment to mitigate the often life-altering effects of increasingly prevalent PTSD, scientists… read more.
Article by Bruce Sylvester. Lisdexamfetamine treatment could be therapeutic for adults with attention-deficit/hyperactivity disorder (ADHD) who also have sluggish cognitive tempo (SCT). The findings were published on June… read more.
Supernus Pharmaceuticals announced that the FDA approved Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age…. read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
